1064662-40-3

1064662-40-3 structure

Name: SNT-207707
Chemical Name: 2-(4-Cyanophenyl)-N,N-bis(3-methylbutyl)-3-[3-(1-pyrrolidinyl)pro pyl]imidazo[1,2-a]pyridine-6-carboxamide hydrochloride (1:1)
CAS Number: 1064662-40-3
Molecular Formula: C₃₂H₄₄ClN₅O
Molecular Weight: 550.17800
Catalog: Research Areas Cancer
Create Date: 2017-11-03 13:45:31
Modify Date: 2025-08-26 17:17:24
SNT-207707 is a selective, potent and orally active melanocortin MC-4 receptor antagonist with an IC50 of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.

Name	2-(4-Cyanophenyl)-N,N-bis(3-methylbutyl)-3-[3-(1-pyrrolidinyl)pro pyl]imidazo[1,2-a]pyridine-6-carboxamide hydrochloride (1:1)
Synonyms	SNT-207707

Description	SNT-207707 is a selective, potent and orally active melanocortin MC-4 receptor antagonist with an IC50 of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Melanocortin Receptor Research Areas >> Cancer Research Areas >> Metabolic Disease
Target	IC50: 8 nM (binding MC-4), 5 nM (function MC-4)[1]
In Vitro	SNT-207707 binds to the MC-4 receptor with an affinity of 8 nM and shows a more than 200-fold selectivity vs. MC-3 and MC-5. SNT207858 is a 22 nM MC-4 antagonist with a 170-fold selectivity vs. MC-3 and a 40-fold selectivity versus MC-5[1].
In Vivo	Single subcutaneous injection of 20 mg/kg of SNT-207707 distinctly increases food intake of the mice. Once daily oral administration of both compounds SNT207858 and SNT-207707 starting the day after tumor implantation significantly reduces the tumor induced weight loss[1].
Animal Admin	Mice[1] Twelve weeks old male CD-1 mice are dosed by gavage with either SNT-207707 or SNT207858 at 60 mg/kg (n=9 per compound). At 1, 3, and 6 hrs post-dose, 3 mice from each compound group are euthanized with CO2. Blood is collected by cardiac puncture, plasma is isolated immediately and then kept on dry ice until analysis[1].
References	[1]. Weyermann P, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One. 2009;4(3):e4774.

123-75-1

1064662-32-3

1064662-40-3

Literature: Santhera Pharmaceuticals (Schweiz) AG Patent: EP1974729 A1, 2008 ; Location in patent: Page/Page column 14; 16; 28 ;

Precursor 2
123-75-1 1064662-32-3
DownStream 0